Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2011 13:00 ET | Source: ACT Biotech, Inc.

Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients

SAN FRANCISCO, Nov. 12, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a clinical stage biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of...
June 02, 2011 09:46 ET | Source: ACT Biotech, Inc.

ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at ASCO

SAN FRANCISCO, June 2, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced...
May 19, 2011 06:00 ET | Source: ACT Biotech, Inc.

ACT BIOTECH to Present Significant Progress in Stomach Cancer Treatment at ASCO

SAN FRANCISCO, May 19, 2011 (GLOBE NEWSWIRE) -- ACT BIOTECH, Inc today announced that it will present encouraging results on the telatinib Phase 2 clinical trial in patients with advanced stomach...
February 28, 2011 11:00 ET | Source: ACT Biotech, Inc.

ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer

SAN FRANCISCO, Feb. 28, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced...
January 20, 2011 14:15 ET | Source: ACT Biotech, Inc.

Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity

SAN FRANCISCO, Jan. 20, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today...